SCHEMBL7654135

SCHEMBL7654135

CC/C(=C(\c1ccccc1)c1ccc(OC(C)Br)cc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 11/20 0.59
CYP19A1 P11511 7/20 0.57
CYP3A4 P08684 2/20 0.57
ESR2 Q92731 6/20 0.57
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
NR1I2 O75469 1/20 0.55
PRKD3 O94806 1/20 0.55
ABCB11 O95342 1/20 0.55
EGFR P00533 1/20 0.55
GBA1 P04062 1/20 0.55
NR3C1 P04150 1/20 0.55
ERBB2 P04626 1/20 0.55
TP53 P04637 1/20 0.55
PRKCG P05129 1/20 0.55
CYP1A2 P05177 1/20 0.55
PRKCB P05771 1/20 0.55
LCK P06239 1/20 0.55
FYN P06241 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7547707 0.86 ESR1 (0.60) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL7547715 0.86 ESR1 (0.60) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL9097407 0.85 ESR1 (0.56) ESR1CYP19A1ESR2HTR6ESRRG
SCHEMBL9097423 0.85 ESR1 (0.56) ESR1CYP19A1ESR2HTR6ESRRG
SCHEMBL10798818 0.85 ESR1 (0.59) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL10798831 0.85 ESR1 (0.59) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL25407318 0.82 ESR1 (0.71) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL1962745 0.82 ESR1 (0.59) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL227233 0.82 ESR1 (0.59) ESR1CYP19A1CYP3A4ESR2MAPT
SCHEMBL10780099 0.79 PTGS2 (0.76) ESR1CYP19A1CYP3A4ESR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489481-B1 COMPOUNDS USED FOR TREATMENT AND/OR PREVENTION OF NEURONAL APOPTOSIS AND/OR EXCITOTOXICITY RELATED NEUROLOGICAL DISORDERS ASTRAZENECA AB (SE) 2002-12-03 US disclosed
EP-1127045-A2 USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AstraZeneca AB (SE) 2001-08-29 EP disclosed
WO-2000025767-A2 USE OF TRIPHENYLBUTENE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS ASTRAZENECA AB (SE) 2000-05-11 WO disclosed